Lung Biotechnology
North America, Maryland, United States, Silver Spring
Description
Lung Biotechnology PBC is engaged in the research and development, and marketing of therapies for pulmonary arterial hypertension (PAH)
Investor Profile
Lung Biotechnology has backed more than 4 startups, with 0 new investments in the last 12 months alone. The firm has led 2 rounds, about 50% of its total and boasts 1 exits across its portfolio.
Investment Focus Highlights
- Concentrates on Corporate Round, Private Equity, Series F rounds (top funding stages).
- Majority of deals are located in United States.
- Strong thematic focus on Health Care, Medical, Medical Device.
Stage Focus
- Corporate Round (50%)
- Private Equity (25%)
- Series F (25%)
Country Focus
- United States (100%)
Industry Focus
- Health Care
- Medical
- Medical Device
- Service Industry
- Wellness
- Biotechnology
- Renewable Energy
FAQ
Frequently Asked Questions
Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.
'%3e%3cpath fill='%23012169' d='M0 0v30h60V0z'/%3e%3cpath stroke='%23fff' stroke-width='6' d='m0 0 60 30m0-30L0 30'/%3e%3cpath stroke='%23C8102E' stroke-width='4' d='m0 0 60 30m0-30L0 30' clip-path='url(%23b)'/%3e%3cpath stroke='%23fff' stroke-width='10' d='M30 0v30M0 15h60'/%3e%3cpath stroke='%23C8102E' stroke-width='6' d='M30 0v30M0 15h60'/%3e%3c/g%3e%3c/svg%3e)
